MORPHINE SULFATE INJ

Morphine Sulfate Inj Adverse Events Reported to the FDA Over Time

How are Morphine Sulfate Inj adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Morphine Sulfate Inj, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Morphine Sulfate Inj is flagged as the suspect drug causing the adverse event.

Most Common Morphine Sulfate Inj Adverse Events Reported to the FDA

What are the most common Morphine Sulfate Inj adverse events reported to the FDA?

Drug Interaction	32 (2.82%)
Hypotension	23 (2.03%)
Overdose	22 (1.94%)
Death	21 (1.85%)
Drug Toxicity	21 (1.85%)
Cardio-respiratory Arrest	19 (1.67%)
Respiratory Depression	15 (1.32%)
Unresponsive To Stimuli	15 (1.32%)
Sedation	14 (1.23%)
Somnolence	14 (1.23%)
Back Pain	12 (1.06%)
	Show More
Pain	12 (1.06%)
Drug Exposure During Pregnancy	11 (.97%)
Drug Withdrawal Syndrome	11 (.97%)
Therapeutic Agent Toxicity	11 (.97%)
Depressed Level Of Consciousness	10 (.88%)
Asthenia	9 (.79%)
Medication Error	9 (.79%)
Agitation	8 (.7%)
Drug Effect Decreased	8 (.7%)
Incorrect Dose Administered	8 (.7%)
Respiratory Failure	8 (.7%)
Vomiting	8 (.7%)
White Blood Cell Count Increased	8 (.7%)
Anaesthetic Complication	7 (.62%)
Areflexia	7 (.62%)
Confusional State	7 (.62%)
Delirium	7 (.62%)
Headache	7 (.62%)
Nausea	7 (.62%)
Post Procedural Complication	7 (.62%)
Apnoea	6 (.53%)
Cardiac Arrest	6 (.53%)
Haemoglobin Decreased	6 (.53%)
Hyperaesthesia	6 (.53%)
Infection	6 (.53%)
Lethargy	6 (.53%)
Myoclonus	6 (.53%)
Oxygen Saturation Decreased	6 (.53%)
Procedural Hypotension	6 (.53%)
Suicide Attempt	6 (.53%)
Accidental Overdose	5 (.44%)
Coma	5 (.44%)
Drug Abuse	5 (.44%)
Fatigue	5 (.44%)
Haemorrhage	5 (.44%)
Inadequate Analgesia	5 (.44%)
Insomnia	5 (.44%)
Malaise	5 (.44%)
Paraesthesia	5 (.44%)
Pleural Effusion	5 (.44%)
Pneumonia Aspiration	5 (.44%)
Pyrexia	5 (.44%)
Renal Impairment	5 (.44%)
Respiratory Distress	5 (.44%)
Respiratory Rate Decreased	5 (.44%)
Abdominal Pain	4 (.35%)
Acute Generalised Exanthematous Pus...	4 (.35%)
Aggression	4 (.35%)
Anxiety	4 (.35%)
Cognitive Disorder	4 (.35%)
Condition Aggravated	4 (.35%)
Disorientation	4 (.35%)
Drug Ineffective	4 (.35%)
Dysarthria	4 (.35%)
Dysphagia	4 (.35%)
Fistula	4 (.35%)
Granuloma	4 (.35%)
Hyperkalaemia	4 (.35%)
Hyperventilation	4 (.35%)
Hypoaesthesia	4 (.35%)
Irritability	4 (.35%)
Mental Status Changes	4 (.35%)
Myalgia	4 (.35%)
Obstetric Procedure Complication	4 (.35%)
Peritonitis	4 (.35%)
Post Procedural Haemorrhage	4 (.35%)
Pulmonary Oedema	4 (.35%)
Renal Failure Acute	4 (.35%)
Respiratory Arrest	4 (.35%)
Sensory Loss	4 (.35%)
Swelling	4 (.35%)
Urinary Retention	4 (.35%)
Abscess	3 (.26%)
Acute Abdomen	3 (.26%)
Altered State Of Consciousness	3 (.26%)
Amnesia	3 (.26%)
Ascites	3 (.26%)
Bacterial Infection	3 (.26%)
Blood Pressure Decreased	3 (.26%)
Blood Pressure Systolic Decreased	3 (.26%)
Bradycardia	3 (.26%)
Catheter Related Complication	3 (.26%)
Chest Pain	3 (.26%)
Cholecystitis	3 (.26%)
Depression	3 (.26%)
Device Failure	3 (.26%)
Diarrhoea	3 (.26%)
Disease Progression	3 (.26%)
Erythema	3 (.26%)
Fall	3 (.26%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Morphine Sulfate Inj, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Morphine Sulfate Inj is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Morphine Sulfate Inj

What are the most common Morphine Sulfate Inj adverse events reported to the FDA?

Neurological	112 (9.87%)
Therapeutic And Nontherapeutic Effe...	61 (5.37%)
Medication Errors	56 (4.93%)
Respiratory	52 (4.58%)
Chemical Injury And Poisoning	45 (3.96%)
Procedural And Device Related Injur...	43 (3.79%)
Cardiac Arrhythmias	37 (3.26%)
Decreased And Nonspecific Blood Pre...	30 (2.64%)
Gastrointestinal Signs	30 (2.64%)
Infections - Pathogen Unspecified	30 (2.64%)
Fatal Outcomes	23 (2.03%)
	Show More
Hematology Investigations	22 (1.94%)
Musculoskeletal And Connective Tiss...	19 (1.67%)
Deliria	18 (1.59%)
Epidermal And Dermal Conditions	17 (1.5%)
Administration Site Reactions	16 (1.41%)
Injuries	15 (1.32%)
Bacterial Infectious	14 (1.23%)
Psychiatric	14 (1.23%)
Cardiac And Vascular Investigations	13 (1.15%)
Muscle	13 (1.15%)
Anxiety Disorders	12 (1.06%)
Mental Impairment	12 (1.06%)
Renal Disorders	12 (1.06%)
Movement Disorders	11 (.97%)
Suicidal And Self-injurious Behavio...	11 (.97%)
Lower Respiratory Tract Disorders	10 (.88%)
Appetite And General Nutritional	9 (.79%)
Physical Examination Topics	9 (.79%)
Urinary Tract Signs	9 (.79%)
Electrolyte And Fluid Balance Condi...	8 (.7%)
Headaches	8 (.7%)
Peritoneal And Retroperitoneal Cond...	8 (.7%)
Vascular Hemorrhagic	8 (.7%)
Gastrointestinal Hemorrhages	7 (.62%)
Gastrointestinal Motility And Defec...	7 (.62%)
Lifestyle Issues	7 (.62%)
Metabolic, Nutritional And Blood Ga...	7 (.62%)
Pleural	7 (.62%)
Sleep Disorders	7 (.62%)
Body Temperature Conditions	6 (.53%)
Changes In Physical Activity	6 (.53%)
Coronary Artery	6 (.53%)
Gallbladder	6 (.53%)
Arteriosclerosis, Stenosis, Vascula...	5 (.44%)
Endocrine Disorders Of Gonadal Func...	5 (.44%)
White Blood Cell	5 (.44%)
Depressed Mood Disorders	4 (.35%)
Enzyme	4 (.35%)
Gastrointestinal Stenosis And Obstr...	4 (.35%)
Hepatic And Hepatobiliary	4 (.35%)
Hepatobiliary	4 (.35%)
Personality Disorders	4 (.35%)
Therapeutic Procedures And Supporti...	4 (.35%)
Thoracic Disorders	4 (.35%)
Vascular	4 (.35%)
Bone And Joint Injuries	3 (.26%)
Breast	3 (.26%)
Cardiac Disorder Signs	3 (.26%)
Central Nervous System Vascular	3 (.26%)
Encephalopathies	3 (.26%)
Exocrine Pancreas Conditions	3 (.26%)
Gastrointestinal Conditions	3 (.26%)
Gastrointestinal Ulceration And Per...	3 (.26%)
Heart Failures	3 (.26%)
Ocular Neuromuscular	3 (.26%)
Peripheral Neuropathies	3 (.26%)
Pulmonary Vascular	3 (.26%)
Seizures	3 (.26%)
Skin Appendage Conditions	3 (.26%)
Spinal Cord And Nerve Root	3 (.26%)
Water, Electrolyte And Mineral	3 (.26%)
Allergic Conditions	2 (.18%)
Anemias Nonhemolytic And Marrow Dep...	2 (.18%)
Angiedema And Urticaria	2 (.18%)
Bile Duct	2 (.18%)
Bone, Calcium, Magnesium And Phosph...	2 (.18%)
Bronchial Disorders	2 (.18%)
Demyelinating	2 (.18%)
Family Issues	2 (.18%)
Fungal Infectious	2 (.18%)
Genitourinary Tract	2 (.18%)
Hemoglobinopathies	2 (.18%)
Investigations, Imaging And Histopa...	2 (.18%)
Microbiology And Serology	2 (.18%)
Nervous System Neoplasms Malignant ...	2 (.18%)
Neuromuscular	2 (.18%)
Platelet	2 (.18%)
Product Quality Issues	2 (.18%)
Protein And Amino Acid Metabolism	2 (.18%)
Protein And Chemistry Analyses	2 (.18%)
Psychiatric And Behavioural Symptom...	2 (.18%)
Renal And Urinary Tract Investigati...	2 (.18%)
Spleen, Lymphatic And Reticulendoth...	2 (.18%)
Tendon, Ligament And Cartilage	2 (.18%)
Vascular Hypertensive	2 (.18%)
Bone Disorders	1 (.09%)
Cranial Nerve Disorders	1 (.09%)
Dental And Gingival Conditions	1 (.09%)
Disturbances In Thinking	1 (.09%)
Embolism And Thrombosis	1 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Morphine Sulfate Inj, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Morphine Sulfate Inj is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.